Equities analysts predict that Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) will post earnings per share of ($0.29) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Oramed Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.23) and the lowest estimate coming in at ($0.34). Oramed Pharmaceuticals reported earnings per share of ($0.18) during the same quarter last year, which would indicate a negative year over year growth rate of 61.1%. The company is expected to announce its next quarterly earnings results on Wednesday, November 27th.
According to Zacks, analysts expect that Oramed Pharmaceuticals will report full-year earnings of ($0.94) per share for the current year, with EPS estimates ranging from ($1.02) to ($0.88). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.85) per share, with EPS estimates ranging from ($0.98) to ($0.61). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Oramed Pharmaceuticals.
Several research firms recently weighed in on ORMP. HC Wainwright set a $20.00 price objective on shares of Oramed Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, September 18th. ValuEngine upgraded shares of Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, LADENBURG THALM/SH SH began coverage on shares of Oramed Pharmaceuticals in a research report on Wednesday, September 11th. They issued a “buy” rating and a $7.00 price objective for the company.
In related news, Director Leonard Sank acquired 25,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was purchased at an average price of $2.92 per share, for a total transaction of $73,000.00. Following the transaction, the director now directly owns 364,999 shares of the company’s stock, valued at approximately $1,065,797.08. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.50% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its position in Oramed Pharmaceuticals by 1,137.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 18,491 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 16,997 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Oramed Pharmaceuticals during the 2nd quarter valued at $155,000. Finally, Renaissance Technologies LLC raised its position in shares of Oramed Pharmaceuticals by 50.5% during the 2nd quarter. Renaissance Technologies LLC now owns 158,098 shares of the biotechnology company’s stock valued at $568,000 after acquiring an additional 53,043 shares during the last quarter. Hedge funds and other institutional investors own 4.82% of the company’s stock.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Featured Article: Blockchain
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.